BN
|
HealthAI Desk•1 views

FDA Approves Eli Lilly's Foundayo: GLP-1 Pill with No Food Restrictions

The FDA has approved Foundayo, an oral GLP-1 weight loss medication from Eli Lilly, which can be taken without food or time restrictions. Clinical trials showed an average 12% weight loss at the highest dose over 72 weeks. Priced from $149 to $349 monthly, it includes insurance options and coupons to lower costs. The approval process took 50 days, the fastest since 2002, with availability starting April 6. Foundayo expands oral GLP-1 options for obesity treatment, competing with Novo Nordisk's Wegovy pill.

Ad slot
FDA Approves Eli Lilly's Foundayo: GLP-1 Pill with No Food Restrictions

The U.S. FDA has approved Foundayo, Eli Lilly's second GLP-1 pill for weight loss, offering greater flexibility with no food or timing restrictions compared to Novo Nordisk's Wegovy.

FDA Approval and Background

  • On Wednesday, the FDA approved orforglipron, marketed as Foundayo, for chronic weight management in adults with obesity or overweight with weight-related conditions.
  • This marks the second oral GLP-1 agonist approved for weight loss, following Wegovy's pill version.
  • The approval was granted under a priority review program, completed in just 50 days—the fastest for a new molecular entity since 2002.

Key Advantages Over Competitors

  • Unlike Wegovy, which must be taken in the morning with a 30-minute wait before eating or drinking, Foundayo can be taken at any time without dietary restrictions.
  • Dr. Dan Skovronsky, Lilly's chief scientific and medical officer, emphasized the design for easy integration into daily life.
  • This flexibility may appeal to individuals with less severe obesity who are hesitant about weekly injections.
Ad slot

Pricing and Access Initiatives

  • Foundayo's list price ranges from $149 to $349 per month for the highest dose, with a maximum out-of-pocket cost of $299 if prescriptions are renewed within 45 days.
  • For commercially insured patients, a coupon can reduce costs to $25 per month.
  • Medicare will cover the drug for some patients starting July 1, with a copay of no more than $50 monthly.
  • These pricing strategies aim to democratize access to obesity treatment, as less than 10% of eligible patients currently use GLP-1 drugs.

Clinical Efficacy and Weight Loss

  • In supporting trials, participants on the highest dose of Foundayo lost an average of 12% of body weight over 72 weeks, compared to 0.9% on placebo.
  • Injectable GLP-1 drugs like Zepbound and Wegovy have shown over 20% weight loss in trials, while Wegovy's pill achieved up to 17% in high doses.
  • Studies also examined switching from injectables to Foundayo: patients moving from Wegovy gained an average of 0.9 kg, while those from Zepbound gained 5 kg, indicating Foundayo helps maintain weight loss.

Safety and Side Effects

  • Common adverse effects mirror other GLP-1 drugs: nausea, constipation, and gastrointestinal issues. Some patients also reported hair loss.
  • Foundayo is approved only for adults; safety and efficacy are not established in children or during pregnancy.
  • Women on birth control pills should consult doctors, as Foundayo may reduce contraceptive effectiveness.

Availability and Market Impact

  • Foundayo will be available via LillyDirect with free home shipping starting April 6, followed by broader pharmacy and telemedicine distribution.
  • Novo Nordisk recently announced a subscription model for Wegovy's pill, priced between $249 and $329 monthly, with a $149 option for low doses.
  • The entry of oral GLP-1 options is transforming the obesity treatment landscape, potentially increasing adoption due to convenience and pricing innovations.
Ad slot